CREB1 and ovarian cancer: Our work unveils the lactate-CREB1 K122la-HMGB1-NETs axis as a metabolic-epigenetic-immune driver of cisplatin resistance and provides a promising nanomedicine strategy for overcoming treatment resistance in ovarian cancer.